IP Library Granted Patent US 9,233,160
Granted Patent B2
US 9,233,160 · App. 14/574,024 · Granted Jan 12, 2016

Oral drug delivery system

Inventors: Su Il Yum (Los Altos, CA); Grant Schoenhard (San Carlos, CA); Arthur J. Tipton (Birmingham, AL); John W. Gibson (Springville, AL); John C. Middleton (Fort Collins, CO); Roger Fu (Saratoga, CA); Michael S. Zamloot (Austin, TX)
Assignee: DURECT CORPORATION
A61K47/26A61K9/48A61K9/4858A61K9/4866A61K31/4458A61K31/485A61K47/14A61K47/38Y10S514/96
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,160
App. No.
14/574,024
Granted
Jan 12, 2016
Kind
B2
Abstract

Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.

Claims (34)

1. A composition comprising:

a drug;

sucrose acetate isobutyrate (SAIB);

a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons; and

a solvent selected from triacetin and ethyl lactate (EL).

2. The composition of claim 1 , wherein the solvent is triacetin.

3. The composition of claim 1 , wherein the CAB has a butyryl content ranging from about 17% to about 38%.

4. The composition of claim 1 , wherein the CAB has an acetyl content ranging from about 13% to about 30%.

5. The composition of claim 1 , wherein the CAB has a hydroxyl content ranging from about 0.8% to about 1.7%.

6. The composition of claim 1 , wherein the CAB has a butyryl content ranging from about 17% to about 38%, an acetyl content ranging from about 13% to about 30%, and a hydroxyl content ranging from about 0.8% to about 1.7%.

7. The composition of claim 1 , wherein the composition comprises from about 0.5 to about 9 weight percent of the CAB.

8. The composition of claim 1 , wherein the composition comprises from about 20 to about 50 weight percent of the solvent.

9. The composition of claim 1 , wherein the composition further comprises from about 1 to about 75 weight percent isopropyl myristate (IPM).

10. An oral dosage form comprising the composition of claim 1 , wherein the composition is contained in a capsule.

11. The oral dosage form of claim 10 , wherein the capsule comprises gelatin or hydroxyl propylmethyl cellulose.

12. The oral dosage form of claim 10 , wherein the capsule is a hard capsule comprising gelatin or hydroxyl propylmethyl cellulose.

13. The composition of claim 1 , wherein the composition comprises:

from about 1 to about 8.6 weight percent of the CAB;

from about 20 to about 50 weight percent of the solvent; and

from about 1 to about 75 weight percent of IPM.

14. A method of providing pain relief to a subject in need thereof, the method comprising:

orally administering to the subject an effective amount of the oral dosage form of claim 13 ,

wherein the drug comprises an opioid.

15. The composition of claim 13 , wherein the composition comprises from 3 to 7.8 weight percent of the CAB.

16. The composition of claim 15 , wherein the CAB has a butyryl content ranging from about 17% to about 38%.

17. The composition of claim 15 , wherein the CAB has an acetyl content ranging from about 13% to about 30%.

18. The composition of claim 15 , wherein the CAB has a hydroxyl content ranging from about 0.8% to about 1.7%.

19. The composition of claim 15 , wherein the CAB has a butyryl content ranging from about 17% to about 38%, an acetyl content ranging from about 13% to about 30%, and a hydroxyl content ranging from about 0.8% to about 1.7%.

20. An oral dosage form comprising the composition of claim 15 , wherein the composition is contained in a capsule.

21. The oral dosage form of claim 20 , wherein the capsule comprises gelatin or hydroxyl propylmethyl cellulose.

22. The oral dosage form of claim 20 , wherein the capsule is a hard capsule comprising gelatin or hydroxyl propylmethyl cellulose.

23. A method of providing pain relief to a subject in need thereof, the method comprising:

orally administering to the subject an effective amount of the composition of claim 1 ,

wherein the drug comprises an opioid.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2015
From: YUM, SU IL; SCHOENHARD, GRANT; TIPTON, ARTHUR J.; GIBSON, JOHN W.; MIDDLETON, JOHN C.
To: DURECT CORPORATION
Reel/Frame 035578/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2015
From: FU, ROGER; ZAMLOOT, MICHAEL S.
To: PAIN THERAPEUTICS, INC.
Reel/Frame 035578/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2015
From: PAIN THERAPEUTICS, INC.
To: DURECT CORPORATION
Reel/Frame 035578/0997 →
Continuity (6)
Continuation 13786118 · Mar 5, 2013
Continuation 13366168 · Feb 3, 2012
Continuation 10737144 · Dec 15, 2003
Provisional Application 60517464 · Nov 4, 2003
Provisional Application 60433116 · Dec 13, 2002
Related Publication 20150196644A1 · Jul 16, 2015